Phase 2 Study of VX-950, Pegasys and Copegus in Hepatitis C

NCT00262483 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C

Interventions

DRUG: VX-950
DRUG: ribavirin
DRUG: peginterferon alfa-2a

Sponsor

Vertex Pharmaceuticals Incorporated